PFE: Pfizer Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 150,147.84
Enterprise Value ($M) 219,747.84
Book Value ($M) 97,204.00
Book Value / Share 17.21
Price / Book 1.54
NCAV ($M) -93,880.00
NCAV / Share -16.63
Price / NCAV -1.60

Profitability (mra)
Return on Invested Capital (ROIC) 0.01
Return on Assets (ROA) 0.01
Return on Equity (ROE) 0.02

Liquidity (mrq)
Quick Ratio 0.69
Current Ratio 0.91

Balance Sheet (mrq) ($M)
Current Assets 43,333.00
Assets 226,501.00
Liabilities 137,213.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 58,496.00
Operating Income 5,259.00
Net Income 2,119.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 8,700.00
Cash from Investing -32,278.00
Cash from Financing 26,066.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-13 13G/A Vanguard Group Inc 8.97 0.97
01-29 13G/A State Street Corp 5.10 1.03
01-26 13G/A BlackRock Inc. 7.70 -1.83

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-03-04 16,493,990 86,777,724 19.01
2024-03-01 6,747,955 46,392,099 14.55
2024-02-29 6,998,301 54,643,160 12.81
2024-02-28 2,891,851 31,010,175 9.33

(click for more detail)

Similar Companies
NUVB – Nuvation Bio Inc. OGN – Organon & Co.
PBH – Prestige Consumer Healthcare Inc. PRGO – Perrigo Company plc
QGEN – Qiagen N.V.


Financial data and stock pages provided by
Fintel.io